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Purpose: To determine patient preference of and ocular discomfort with ﬁ  xed combination 
brinzolamide/timolol compared with ﬁ  xed combination dorzolamide/timolol.
Methods: In a prospective, double-masked, randomized, active-controlled, crossover, 
multicenter study, patients received 1 drop of brinzolamide/timolol and dorzolamide/timolol 
in both eyes on consecutive days in random order. Ocular discomfort was rated 1 minute after 
instillation of each medication, and preference was noted on Day 2. Adverse events, if any, 
were solicited at each visit.
Results: 127 subjects with ocular hypertension or open-angle glaucoma were included in the 
intent-to-treat analysis. Of the 106 subjects who expressed a drug preference, 79.2% preferred 
brinzolamide/timolol (p   0.0001). Ocular discomfort scores were signiﬁ  cantly higher 
with dorzolamide/timolol than brinzolamide/timolol (2.9 vs 1.4, respectively; p   0.0001). 
Signiﬁ  cantly more patients reported ocular pain and discomfort after dorzolamide/timolol 
instillation and transient blurred vision after brinzolamide/timolol instillation.
Conclusions: Patients with ocular hypertension or open-angle glaucoma preferred the 
brinzolamide/timolol ﬁ  xed combination over the dorzolamide/timolol ﬁ  xed combination. This is 
likely due to the greater ocular discomfort associated with dorzolamide/timolol. The differences 
in preference, discomfort, and adverse events are likely attributable to formulation differences 
given the similarities of the active ingredients. Stronger patient preference for brinzolamide/
timolol may lead to better therapeutic compliance.
Keywords: brinzolamide/timolol, dorzolamide/timolol, patient preference, ocular discomfort, 
open-angle glaucoma or ocular hypertension
Introduction
Reduction of intraocular pressure (IOP) is the only established therapy for the 
management of ocular hypertension and open-angle glaucoma. Topical IOP-lowering 
medications remain the primary treatment option for a majority of patients. A signiﬁ  cant 
number of patients with ocular hypertension or open-angle glaucoma will require more 
than one medication to achieve adequate control of  IOP. Nearly 40% of subjects in the 
Ocular Hypertension Treatment Study required two or more medications to achieve a 
20% reduction in IOP (Kass et al 2002).
Adjunctive therapy involving multiple medication bottles adds complexity compared 
with single-agent monotherapy, and may introduce a washout effect if co-administered 
drops are not spaced adequately in time (Fechtner and Realini 2004; Khouri et al 2007). Clinical Ophthalmology 2008:2(3) 624
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Some of these issues have been identiﬁ  ed as barriers to 
therapeutic compliance (Tsai et al 2003). Fixed combinations 
of commonly co-administered IOP-lowering agents have been 
developed to minimize these issues, offering simpliﬁ  cation 
of the dosing regimen and elimination of the washout effect 
(Fechtner and Realini 2004; Khouri et al 2007).
Tolerability has also been identified as a barrier to 
compliance (Tsai et al 2003). Ocular comfort is an important 
aspect of tolerability. Tolerability is an important characteristic 
of ﬁ  xed combination therapies. For instance, the most common 
adverse events associated with dorzolamide (Trusopt®, 
Merck and Co., Inc., Whitehouse Station, NJ, USA) are 
ocular burning, stinging, and discomfort, and taste perversion 
(Trusopt prescribing information 2005); a similar safety 
proﬁ  le is observed with the dorzolamide 2%/timolol 0.5% 
ﬁ  xed combination (Cosopt®, Merck and Co., Inc., Whitehouse 
Station, NJ, USA) (Cosopt prescribing information 2006).
Recently, timolol 0.5% and brinzolamide 1% (Azopt®, 
Alcon Laboratories, Inc., Ft. Worth, TX, USA) have 
been formulated in a ﬁ  xed combination (Azarga™, Alcon 
Laboratories, Inc., Ft. Worth, TX, USA). The most common 
side effects with brinzolamide are blurred vision and taste 
perversion; fewer than 5% of patients report ocular discomfort 
associated with brinzolamide use in clinical trials (Alcon 
Laboratories, Inc. 2003). In a comparative analysis from 
2 prospective clinical trials of brinzolamide and dorzolamide, 
dorzolamide was associated with signiﬁ  cantly more ocular 
discomfort (p = 0.001), while the brinzolamide group 
experienced more blurred vision (p   0.05; Silver 2000).
The goal of this study was to determine patient preference 
of brinzolamide/timolol compared to dorzolamide/timolol 
after a single drop of each medication was administered to 
both eyes.
Methods
This was a prospective, double-masked, randomized, active-
controlled, crossover, multi-center study conducted at 
10 clinical sites within the United States. The objective of the 
study was to evaluate the patient preference of a single drop of 
each medication, brinzolamide 1%/timolol 0.5% ophthalmic 
suspension and dorzolamide 2%/timolol 0.5% ophthalmic 
solution, administered to both eyes on 2 consecutive days. 
The protocol was approved by all relevant Institutional 
Review Boards, the study was performed in compliance 
with the ethical principles of the Declaration of Helsinki and 
Good Clinical Practice, and all participating patients provided 
written informed consent. The clinical trial registration 
number for this study was NCT00576342.
Subjects
Patients 18 years of age or older, diagnosed with open-angle 
glaucoma or ocular hypertension who were on a stable IOP-
lowering medication monotherapy regimen for at least 30 days 
prior to the Screening Visit, were eligible to enroll in the study 
if their IOP, in the opinion of the investigator, did not present 
a risk to the patient’s ocular health. Patients were excluded if 
they met any of the following criteria: best corrected visual 
acuity was worse than 0.60 logMAR (20/80 Snellen) in either 
eye; use of contact lenses, topical or systemic corticosteroids, 
antihistamines, analgesic drugs, or topical cyclosporine within 
30 days of the Screening Visit or during the course of the 
study; use of artiﬁ  cial tears within 3 days of the Screening 
Visit or during the course of the study; active infectious or 
noninfectious conjunctivitis, keratitis, scleritis or uveitis 
in either eye at the Screening Visit; history of intraocular 
conventional surgery or laser surgery within 90 days of the 
Screening Visit or during the course of the study; history of 
or active chronic, recurrent or current severe inﬂ  ammatory 
eye disease, clinically significant or progressive retinal 
disease such as retinal degeneration, diabetic retinopathy, or 
retinal detachment in either eye; history of severe or serious 
hypersensitivity to timolol maleate, topical or oral carbonic 
anhydrase inhibitors, sulfonamide derivatives, or to any 
components of the study medications; history of severe, 
unstable or uncontrolled cardiovascular, hepatic, or renal 
disease (eg, sinus bradycardia, overt cardiac failure, greater 
than ﬁ  rst degree atrioventricular block, cardiogenic shock, 
clinically relevant angina or uncontrolled hypertension), or 
bronchial asthma or severe chronic obstructive pulmonary 
disease that could preclude the safe administration of a topical 
beta-blocker. In addition, women of childbearing potential 
(those who were not surgically sterilized or at least 2 years 
post-menopausal) were not enrolled if any of the following 
conditions existed: they were pregnant; had a positive result 
on the urine pregnancy test at the Screening Visit; intended to 
become pregnant during the study period; were breast-feeding; 
or were not using highly effective birth control methods.
Procedures
The study was a 3-day, multi-center, double-masked, active- 
controlled, randomized, crossover design. There were a total 
of 3 visits on consecutive days in this study: The Screening 
Visit (Day 0), followed by 2 additional visits (Day 1 and 
Day 2). The Exit Visit was completed on Day 2, or when 
the patient discontinued study participation.
After providing informed consent, participating patients 
underwent a Screening Examination (Day 0) consisting of  the Clinical Ophthalmology 2008:2(3) 625
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following: collection of demographic information, medical 
history, current and previous medications; administration 
of a pregnancy test (if applicable); and an eye examination 
including the assessment of IOP, visual acuity (VA), undilated 
fundus and slit-lamp examination. Patients who met the 
inclusion/exclusion criteria were instructed to discontinue 
their topical IOP-lowering medication at the Screening Visit, 
for the 3-day duration of the study. Between 12 noon and 
8 PM on Day 0, the designated study personnel instilled 1 drop 
of brinzolamide/timolol in 1 eye and 1 drop of dorzolamide/
timolol in the fellow eye in double-masked and randomized 
fashion, and patients were observed for adverse events. This 
also allowed patients to experience the range of discomfort 
that they could expect during the course of the study and more 
accurately score their perceptions of drop comfort. If both 
study medications were tolerated, the patient was discharged 
and asked to return in 1 day at approximately the same time 
on each of the next 2 days. For the Day 1 and Day 2 Visits, 
patients were randomized in a 1:1 ratio to receive either 
brinzolamide/timolol at the Day 1 Visit and dorzolamide/
timolol at the Day 2 Visit, or dorzolamide/timolol at the 
Day 1 Visit and brinzolamide/timolol at the Day 2 Visit. The 
assigned treatment was administered by designated study site 
personnel as a single drop in both eyes. At all 3 visits, dosing 
was done at approximately the same time between 12 noon 
and 8 PM. Patients completed an Ocular Discomfort Scale 
(0 “no discomfort” to 9 “substantial discomfort”) approxi-
mately 1 minute after the study medication was instilled on 
the Day 1 and Day 2 Visits. After completion of the Ocular 
Discomfort Scale on the Day 2 Visit each patient completed a 
Preference Question for which they checked one of these pos-
sible responses: “Prefer 1st Medication”, “No Preference”, 
or “Prefer 2nd Medication.” Adverse events, deﬁ  ned as any 
untoward changes (expected or unexpected) in a patient’s 
ophthalmic and/or medical health that occurred after initia-
tion of study treatment, were obtained at each study visit as 
solicited or unsolicited comments from the patients and as 
observations by the investigators (at Day 0, IOP was mea-
sured and undilated fundus and slit-lamp examinations were 
performed). All adverse events were coded using a Medical 
Dictionary for Regulatory Affairs (version 10.0) and received 
independent causality assessments from the investigator and 
the Medical Monitor.
Statistical analysis
The primary statistical objective of this study was to dem-
onstrate that patient preference for brinzolamide/timolol 
was superior to that of dorzolamide/timolol with respect to 
ocular comfort using a crossover study design. The primary 
efﬁ  cacy parameter was the percentage of patients with a 
stated preference for either study medication, assessed in the 
patients who stated an actual preference, using a chi-square 
test. Primary inference for the test of superiority was based 
on the intent-to-treat data set. Differences in the ocular 
discomfort of the two study medications were analyzed as 
a supportive efﬁ  cacy measure. An analysis of variance was 
used to compare the differences in mean ocular discomfort 
score between the two study medications.
Assuming that up to 13% of patients would express 
no preference for either study medication, approximately 
115 patients were enrolled to ensure at least 100 evaluable 
patients with a stated study medication preference to provide 
approximately 90% power to detect a difference between 
equal preference for either study medication (50% prefer one 
and 50% prefer the other) and a preference for one or the other 
of at least 66%. This estimate was based on a 2-sided, 1 sample 
chi-square test at the α = 0.05 level of signiﬁ  cance.
Results
Patient disposition and demographics
A total of 129 patients were enrolled in the study; 63 were 
randomized to receive brinzolamide/timolol followed 
by dorzolamide/timolol, and 66 were randomized to the 
opposite sequence. All 129 patients received at least 1 dose 
of study medication and were included in the safety analysis. 
Two patients (1 in each randomization sequence) did not 
complete the patient preference questionnaire and ocular 
discomfort assessments and were therefore not evaluable 
for either the intent-to-treat analysis or the per protocol 
analysis. An additional 3 patients were excluded from the per 
protocol analysis due to the use of a disallowed medication 
at Screening. Per protocol analyses conﬁ  rmed intent-to-treat 
analyses.
Demographics of the 129 participating patients are given in 
Table 1. Patients were predominantly Caucasian (72.9%), 50% 
were female, and their mean age was 66.2 ± 11.4 years.
Patient preference and ocular discomfort
Patient preference results are illustrated in Figure 1. Of the 
106 patients in the intent-to-treat analysis who expressed a 
preference, 79.2% (84/106) preferred brinzolamide/timolol 
over dorzolamide/timolol and 20.8% preferred dorzolamide/
timolol over brinzolamide/timolol (p   0.0001). Only 16.5% 
(21/127) of patients expressed no preference.
Ocular discomfort results are given in Figure 2. In the 
overall intent-to-treat analysis, mean discomfort scores Clinical Ophthalmology 2008:2(3) 626
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were signiﬁ  cantly lower for brinzolamide/timolol than for 
dorzolamide/timolol (1.4 ± 1.6 vs 2.9 ± 2.5, respectively; p 
  0.0001). Similarly, among those patients who expressed a 
preference for one drug over the other, brinzolamide/timolol 
was signiﬁ  cantly more comfortable than dorzolamide/timolol 
(1.5 ± 1.5 vs 3.3 ± 2.5, respectively; p   0.0001).
Adverse events
Adverse events are summarized in Table 2. Ocular irritation 
(deﬁ  ned as burning) and eye pain (deﬁ  ned as stinging) were 
more common with dorzolamide/timolol, and blurred vision 
was more common with brinzolamide/timolol. In this study, 
discomfort was mild to moderate in severity in both treatment 
groups, and no patients left the study due to adverse events.
Discussion
In this prospective, randomized, double-masked clinical trial, 
4 out of 5 patients with a preference preferred brinzolamide/
timolol ﬁ  xed combination over dorzolamide/timolol ﬁ  xed 
combination (79.2% preferred brinzolamide/timolol and 
20.8% preferred dorzolamide/timolol).
Because the brinzolamide/timolol ﬁ  xed combination is 
formulated as a suspension, it may be more likely to cause tran-
sient blurring of vision than the dorzolamide/timolol ﬁ  xed com-
bination, which is formulated as a solution. In the present study, 
signiﬁ  cantly more patients reported blurred vision after instilling 
brinzolamide/timolol compared with dorzolamide/timolol. 
Despite these observations, most patients in this study still pre-
ferred brinzolamide/timolol, suggesting that the blurred vision 
occurring with brinzolamide/timolol was less annoying than the 
ocular discomfort experienced with dorzolamide/timolol.
One important reason for their preference was ocular 
comfort. The patients in our study reported signiﬁ  cantly lower 
ocular discomfort scores after instilling brinzolamide/timolol 
compared to dorzolamide/timolol. In fact, the mean discom-
fort score for dorzolamide/timolol was more than twice as high 
as the mean score for brinzolamide/timolol: 2.9 versus 1.4, 
respectively, in the intent-to-treat analysis. Among the 83.5% 
of patients who preferred one medication over the other, the 
difference was 3.3 versus 1.5, respectively. Ocular comfort 
is a quality that glaucoma patients desire in an IOP-lowering 
medication: in a willingness-to-pay analysis, Jampel et al 
(2003) found that nearly 75% of patients would pay more for a 
comfortable medication than for a drug associated with sting-
ing and burning upon instillation; on average, they would pay 
approximately 25% more for the comfortable medication.
Signiﬁ  cantly more patients in our study reported eye 
irritation and eye pain as adverse events after instillation 
of dorzolamide/timolol compared to brinzolamide/timolol. 
Combined, more than four times more patients reported 
these adverse events after dorzolamide/timolol compared 
to brinzolamide/timolol (32 vs 8, respectively; see Table 2). 
While no subject discontinued participation based on study 
Table 1 Demographics of participating patients (n = 129)
Mean age (yr) 66.2 ± 11.4
Gender, n (%)
 Female 65  (50.4)
 Male 64  (49.6)
Race, n (%)
 Caucasian 94  (72.9)
  Black or African-American 23 (17.8)
 Hispanic 10  (7.8)
 Other 2  (1.6)
Diagnosis, n (%)
  Open-angle glaucoma 100 (77.5)
  Ocular hypertension 29 (22.5)
Figure 1 Percentage patient preference among those stating a preference (n = 106; 
p   0.0001).
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medication discomfort, this 3-day trial involving motivated 
and compensated research subjects is unlikely to be 
representative of a typical clinical patient population using 
medications chronically and without compensation.
Little is known about the relationship between tolerability 
and therapeutic compliance. In a systematic classiﬁ  cation 
of the reasons why patients fail to take their glaucoma 
medications as prescribed, Tsai et al (2003) identified 
side effects as a potential barrier to compliance. On a 
representative sample of French patients treated with an 
IOP-lowering treatment, Nordmann et al (2003) found 
some associations between burning and stinging, vision- 
related quality of life and compliance: patients with 
declared adverse events more often missed instillations. 
Day et al (2006) reported associations between treatment 
satisfaction and some adverse events (ocular irritation, 
conjunctival hyperemia). Lastly, Nordmann et al (2007) 
found that treatment characteristics are associated with 
patient preference. Therefore, it is not unreasonable to 
believe that patients may take a medication less frequently 
than prescribed if it is associated with signiﬁ  cant side effects, 
including ocular discomfort. This is particularly important 
when associations between compliance and lack of IOP 
control have been reported (Konstas et al 2000).
Both of these ﬁ  xed combinations contain timolol and 
a topical carbonic anhydrase inhibitor. The differences in 
ocular discomfort and patient preference observed in this 
study likely arise from formulation differences, rather than 
to differences attributable to the drug molecules themselves. 
The dorzolamide molecule requires an acidic pH to optimize 
solubility. Thus, both the dorzolamide 2% ophthalmic solu-
tion (Merck and Co., Inc. 2005) and the dorzolamide/timolol 
ﬁ  xed combination (Merck and Co., Inc. 2006) are formulated 
with a pH around 5.6. Brinzolamide is adequately soluble 
at the more physiologic pH of 7.2 (Alcon Laboratories, Inc. 
2003). Numerous studies have demonstrated greater comfort 
and higher patient preference rates for brinzolamide over 
dorzolamide (Barnebey and Kwok 2000; Silver 2000; Stewart 
et al 2004; Tsukamoto et al 2005a, b). The difference in pH 
of the two ﬁ  xed combinations may explain the difference in 
comfort reported by the participants.
This study is strengthened by its rigorous prospective, 
double-masked, randomized, crossover design, and its sample 
size providing adequate power to detect clinically signiﬁ  cant 
differences in preference. This avoids the subjectiveness of 
tolerability comparison studies that take place at the time of 
an unmasked, nonrandomized switch from one medication 
to another. The crossover design utilized in this study allows 
for within-patient comparisons rather than between-patient 
comparisons as necessitated by parallel-group designs, 
reducing the variability associated with between-groups 
comparisons. Limitations of this study include the lack of a 
wash-out period prior to study initiation and the deﬁ  nition of 
“stable use” of glaucoma medications to be 30 days. While 
these limitations could introduce bias due to potential side 
effects of previous glaucoma medications, this bias should 
be minimized by the fact that both study medications were 
administered to each patient in random order.
In summary, this study has demonstrated that patients 
with ocular hypertension or open-angle glaucoma prefer 
the brinzolamide/timolol fixed combination over the 
dorzolamide/timolol fixed combination by a margin of 
nearly 4 to 1. This may be related to the greater ocular 
discomfort associated with dorzolamide/timolol compared 
with brinzolamide/timolol. The differences in preference and 
discomfort are likely attributable to formulation differences 
given the similarities of the active ingredients. Stronger 
patient preference for the greater comfort of brinzolamide/
timolol may lead to better therapeutic compliance.
Brinzolamide/Timolol Preference 
Study Group (all USA)
Jason Bacharach, MD, North Bay Associates, Inc., 
Petaluma, CA. Joseph I Markoff, MD, Philadelphia Eye 
Table 2 Summary of adverse events, n (%)
Brinzolamide/timolol Dorzolamide/timolol p value
Ocular irritation 7 (5.5) 22 (17.3) 0.0029
Ocular pain 1 (0.8) 10 (7.9) 0.0053
Blurred vision 19 (14.8) 1 (0.8)   0.0001
Other
  Foreign body sensation 1 (0.8) 0 (0) –
  Increased tearing 0 (0) 1 (0.8) –
  Taste perversion 1 (0.8) 0 (0) –Clinical Ophthalmology 2008:2(3) 628
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